

NCO HEALTHCARE CONSULTING LIMITED

Directors' report and unaudited financial statements

For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025

Registered number 766623

NCO Healthcare Consulting Limited

<i>Contents</i>	<i>Page</i>
Company information	1
Directors' report	2 - 3
Statement of directors' responsibilities	4
Statement of comprehensive income	5
Statement of financial position	6
Statement of changes in equity	7
Statement of cash flows	8
Notes to the financial statements	9 - 12

NCO Healthcare Consulting Limited

Directors and other information

Director	Olayinka Aremu (appointed 24 June 2024)
Company Secretary	Oluwaseun Aremu (appointed 24 June 2024)
Company Registration Number	766623
Registered Office	60A Lake Drive Kilminchy Portlaoise Laois R32 HN6Y Ireland (effective from 24 June 2024)

NCO Healthcare Consulting Limited

Directors' report

The Director submits her report together with the unaudited financial statements of NCO Healthcare Consulting Limited (the "Company") for the financial period from 24 June 2024 (date of incorporation) to 23 June 2025.

Nature of business and principal activities

The Company is a designated activity company which was incorporated on 24 June 2024, under the laws of Ireland with a registration number 722314.

The Company has been established to acquire, manage, hold, sell, dispose of, finance and trade in all forms of financial assets and intends to carry on the business of a qualifying company within the meaning of section 110 of the Taxes Consolidation Act 1997 (as amended).

Business review and future developments

The Company had not commenced operations by 23 June 2025.

Results and dividends for the financial period

The results for the financial period and the Company's financial position at the end of the financial period are set out on pages 5 and 6 respectively. The profit before taxation for the financial period was EUR Nil. The Director does not recommend the payment of a dividend.

Director, the company secretary and their interests

The Director and Company Secretary of the Company are listed below and except where indicated, have served for the entire financial period.

Olayinka Aremu (appointed 24 June 2024) – 100% shares held
Oluwaseun Aremu (appointed 24 June 2024) – Nil% shares held

The Director and Company Secretary had no material interest in any contract of significance in relation to the business of the Company other than that disclosed below. During the financial period, the Director and Secretary did not hold an interest in the shares of the Company.

Related party transactions

There were no significant related party transactions other than those disclosed in the financial statements.

Significant subsequent events

There were no significant subsequent events since the end of the financial period until the date of approving of this report that would require an adjustment to or disclosure in the financial statements.

Financial risk management

As the Company had not commenced operations by 23 June 2025, the Director believes that the Company did not face any risks or uncertainties as at 23 June 2025.

Shareholder's meetings

The shareholders' rights and the operations of shareholders meetings are defined in the Company's Constitution and comply with the Companies Act 2014. The Company holds a general meeting each financial period as its annual general meeting. The annual general meeting is specified in the notice sent out for the meeting. Other general meetings may be convened from time to time by the Director in such manner as provided by the Companies Act 2014.

Issue of shares

The authorised share capital of the Company is EUR50,000 and is divided into 50,000 shares of EUR1 each, of which all 50,000 shares have been issued. The issued share is held by Olayinka Aremu (the "Shareholder"). The share capital is disclosed in Note 9.

Dividends

The Director did not propose the payment of a dividend in the current financial period.

Political donations

The Company did not make any political donations during the financial period.

NCO Healthcare Consulting Limited

Directors Report (continued)

Going concern

The Company's financial statements for the financial period ended 23 June 2025 have been prepared on a going concern basis. The Director anticipates that upon the commencement of operations the financial assets will generate sufficient cash flow on an ongoing basis to meet the Company's liabilities as they fall due.

Adequate accounting records

The Director is responsible for ensuring that adequate accounting records, as outlined in Section 281 - 285 of the Companies Act 2014, are kept by the Company. The measures taken by the Director to ensure compliance with the Company's obligation to keep adequate accounting records are the use of appropriate systems and procedures and by ensuring that a competent service provider is responsible for the preparation and maintenance of the accounting records. The accounting records are kept at 60A Lake Drive, Kilminchy, Portlaoise, Laois.

Audit exemption

The Company is availing itself of the audit exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014 on the grounds that it complies with the requirements of sections 350 and 360 of the Companies Act 2014. The Director confirms that they have not received a notice requesting an audit in accordance with section 335(1) of the Companies Act 2014. As set out on page 5, the Director acknowledges the obligations of the Company to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial period and of its profit or loss for such period and otherwise comply with the provisions of the Companies Act 2014.

This report was approved by the Board and authorised for issue on 6 January 2026 and signed on its behalf by:

Signed by:

C2D1D3E51864498...
Olayinka Aremu
Director

NCO Healthcare Consulting Limited

Statement of director's responsibilities

The Director is responsible for preparing the Directors' Report and the financial statements in accordance with the Companies Act 2014 and the applicable regulations.

Irish company law requires the Directors to prepare financial statements for each financial period. Under the law, the Director has elected to prepare the financial statements in accordance with International Financial Reporting Standards as adopted by the European Union ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial period end date and of the profit or loss of the Company for the financial period and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies for the Company Financial Statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Director is responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014.

They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

NCO Healthcare Consulting Limited

Statement of comprehensive income

For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025

	Notes	Financial period ended 23 June 2025 EUR
Other income		
Other income	3	-
Operating expenses		
Administration expenses	4	-
Operating loss for the financial period before taxation		
Corporation tax charge	6	-
Profit for the financial period after taxation		-
Other comprehensive income for the financial period		-
Total comprehensive income for the financial period attributable to the shareholders		-

All amounts relate to continuing operations.

The accompanying notes form an integral part of the financial statements.

NCO Healthcare Consulting Limited**Statement of financial position**
As at 23 June 2025

	Notes	As at 23 June 2025 EUR
Current assets		
Other receivables	7	50,000
		<u>50,000</u>
Total assets		<u>50,000</u>
Current liabilities		
Trade and other payables	8	-
		<u>-</u>
Total liabilities		<u>-</u>
Equity		
Called-up share capital presented as equity	9	50,000
Retained earnings		-
Total equity		<u>50,000</u>
Total equity and liabilities		<u>50,000</u>

The accompanying notes form an integral part of the financial statements.

I, as Director of NCO Healthcare Consulting Limited, state that:

- (a) the Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the Company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied;
- (c) the shareholder of the Company have not served a notice on the company under s.334(1) in accordance with s.334(2);
- (d) we acknowledge the Company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial period and of its profit or loss for such a period and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company.

The financial statements were approved by the Board on 6 January 2026 and signed on its behalf by:

Signed by:

 C2D1D3E51864496...
Olayinka Aremu
 Director

NCO Healthcare Consulting Limited

Statement of changes in equity

For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025

Financial period ended 23 June 2025	Called up share capital EUR	Retained earnings EUR	Total equity EUR
As at 24 June 2024	-	-	-
Share capital issued during the financial period	50,000	-	50,000
As at 23 June 2025	50,000	-	50,000

The accompanying notes form an integral part of the financial statements.

NCO Healthcare Consulting Limited

**Statement of cash flows
For the financial period ended 23 June 2025**

The Company did not trade during the financial period and received no income and incurred no expenditure. Consequently, there were no cash flows in the Company during the financial period.

NCO Healthcare Consulting Limited**Notes to the financial statements****For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025****1. General information**

The Company was incorporated on 24 June 2024, with registration number 766623 and has a registered office 60A Lake Drive, Kilminchy, Portlaoise, Laois, R32 HN6Y, Ireland. The Company is a limited company with limited. The Company did not trade during the period.

2. Summary of material accounting policies

The principal accounting policies that the Company applied in preparing its financial statements for the financial period ended 23 June 2025 are set out below:

(a) Basis of preparation**Statement of compliance**

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

Going concern

The Director has prepared the financial statements on the going concern basis which assumes that the Company will continue in operational existence for the foreseeable future and will have adequate funds available to meet their obligations as they fall due for a period of at least 12 months from the date of approval of the financial statements. The Going Concern section of the Directors’ Report provides the basis for this assumption.

Functional and presentation currency

The financial statements are presented in Euro denoted by the symbol “EUR”, which is both the Company’s functional currency and presentation currency. There were no exchange differences recognised in profit or loss during the financial period. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Assets and liabilities in foreign currencies have been translated at the exchange rates in effect at the statement of financial position date. All exchange differences are dealt with in arriving at the profit or loss before taxation.

(b) Administration expenses

All administration expenses are accounted for on an accrual basis.

(c) Cash and cash equivalents

Cash and cash equivalents may include cash in hand and deposits on call with banks that are convertible into known amounts of cash with an insignificant risk of changes in value and with original maturities of less than three months.

(d) Share capital and dividends

Share capital is issued in Euro. Dividends are recognised as liabilities in the financial period in which they are paid. No dividends were approved during the financial period.

(e) Taxation

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the statement of comprehensive income except to the extent that it relates to items recognised directly in equity or other comprehensive income. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on timing differences which arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. Deferred tax is not recognised on permanent differences arising because certain types of income or expense are non-taxable or are disallowable for tax or because certain tax charges or allowances are greater or smaller than the corresponding income or expense.

Deferred tax is provided in respect of the additional tax that will be paid or avoided on differences between the amount at which an asset (other than goodwill) or liability is recognised in a business combination and the corresponding amount that can be deducted or assessed for tax. Deferred tax is measured at the tax rate that is expected to apply to the reversal of the related difference, using tax rates enacted or substantively enacted at the balance sheet date. Deferred tax balances are not discounted.

(f) Use of estimates and judgements

The preparation of the financial statements requires management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources.

NCO Healthcare Consulting Limited

Notes to the financial statements (continued)

For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025

2. Summary of material accounting policies (continued)

Key judgement and estimate used during the financial period include:

- Estimation of accrued expenses, if any. The accruals of the Company are prepared based on previous knowledge of such expenses and are reviewed on an on-going basis.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year, or in the year of the revision and future years if the revision affects both current and future years.

2. Other income

The Company has not commenced operations, hence the Company did not earn any income during the financial period ended 23 June 2025.

3. Administration expenses

	For the financial period ended 23 June 2025 EUR
Administrative expenses	<hr style="border: 0.5px solid black;"/> - <hr style="border: 0.5px solid black;"/> -

The Company incurred no administrative expenses during the financial period as all expenses are paid centrally. The Company has no employees and the Director received no remuneration during the financial period. Accounting and other services have been outsourced to the Corporate Administrator. The Company is availing itself of the audit exemption provided for by the Companies Act 2014, therefore, there are no audit, tax compliance or other assurance or non-audit services provided by an independent auditor.

4. Staff numbers and costs

The Company has no employees. The Director received no remuneration from the Company in respect of qualifying services rendered during the financial period.

5. Corporation tax charge

	Financial period ended 23 June 2025 EUR
Corporation tax based on profit for the financial period	<hr style="border: 0.5px solid black;"/> - <hr style="border: 0.5px solid black;"/> -

The current tax charge for the financial period is higher than the current charge that would result from applying the standard rate of Irish corporation tax to profit on ordinary activities. The difference are explained below:

	Financial period ended 23 June 2025 EUR
Operating profit before taxation	<hr style="border: 0.5px solid black;"/> -
Profit on ordinary activities at the standard rate of Irish corporation tax for the financial period of 12.5%	<hr style="border: 0.5px solid black;"/> - <hr style="border: 0.5px solid black;"/> -

6. Other receivables

	23 June 2025 EUR
Share capital receivable	<hr style="border: 0.5px solid black;"/> 50,000
Balance at the end of the financial period	<hr style="border: 0.5px solid black;"/> 50,000 <hr style="border: 0.5px solid black;"/>

7. Trade and other payables

NCO Healthcare Consulting Limited**Notes to the financial statements (continued)****For the financial period from 24 June 2024 (date of incorporation) to 23 June 2025**

The Company incurred no administrative expenses during the financial period as all expenses are paid centrally by the Company. As such the Company did not have any trade or other payables at the financial period end.

8. Called up share capital presented as equity

	23 June 2025
	EUR
<i>Authorised</i>	
50,000 ordinary shares of EUR 1 each	50,000
	<u>50,000</u>
<i>Called up, allotted and unpaid capital</i>	
1 ordinary share of EUR 1 each	50,000
	<u>50,000</u>

Ordinary shares are not redeemable and are classified as equity as per the Company's constitution. The Company has issued 50,000 shares which are held by Olayinka Aremu.

9. Financial risk management

The Director has overall responsibility for the establishment and oversight of the Company's risk management framework. This note presents information about the Company's exposure to each of the significant risks and the Company's management of these risks.

As the Company had not commenced trading operations by 23 June 2025, the Director believes that the Company did not face any significant risks or uncertainties as at 23 June 2025.

10. Ultimate controlling party

The Company's controlling party is Olayinka Aremu who holds 100% shares.

11. Related party transactions

Parties are considered to be related if one party has the ability to control the other party or is able to exercise significant influence over the other party, in making financial or operational decisions.

There were no related party transactions requiring disclosure.

12. Commitments and contingent liabilities

There were no contingent liabilities or commitments as of 23 June 2025. Contingent liabilities are assessed continually to determine whether transfers of economic benefits have become probable. Where future transfers of economic benefits change from previously disclosed contingent liabilities, provisions are recognised in the financial period in which the changes in probability occur.

13. Subsequent events

There were no significant subsequent events since the end of the financial period up to the date of approval of this report that would require an adjustment to or disclosure in the financial statements.

14. Approval of the financial statements

The Board of Directors approved the financial statements on 6 January 2026.